Royalty Pharma报告第二季度业绩

2026-08-05 19:13

Royalty Pharma press release (RPRX): Q2 net income of $81M
Revenue of $674M (+16.4% Y/Y) misses by $84.88M.
Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14%
Raised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million to $3,500 million

More on Royalty Pharma

Royalty Pharma: At The Right P/E, I'm In (But Not Here)
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Royalty Pharma Q2 2026 Earnings Preview
Royalty Pharma to pay up to $425M for royalty interest in AstraZeneca’s cliramitug